Japan and U.S. Approvals Turn Companion Diagnostics into Commercial Platforms

Regulatory wins in Japan and the U.S. are recasting companion diagnostics as scalable platforms that support therapy selection, pharma partnerships, and recurring revenue.

Updated

What is this trend?

Japan and U.S. approvals are turning companion diagnostics into commercial platforms that steer therapy selection and generate recurring pharma-linked revenue.

  • MRD and liquid biopsy are moving from monitoring to treatment-selection CDx roles.
  • Single approvals are being folded into broader platforms with multiple indications.
  • Commercial value now depends on validation, software, lab scale, and cross-border execution.
  • Pharma partnerships are becoming the main route to recurring utilization and pull-through.

What’s the latest?

Natera’s PMDA approval in Japan for Signatera in muscle-invasive bladder cancer pushes MRD into therapy selection, not just recurrence monitoring: the assay is now a companion diagnostic for adjuvant

Companion diagnostics become commercial platforms, FDA makes AI validation the moat, and pathology consolidates

How it developed

  1. Decentralized diagnostics become workflow platforms, blood screening enters clinical care, and liquid biopsy turns decision support
    • Liquid Biopsy Moves from Panel Testing to Multi-Omics Decision Support

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.

Related trends

Stay ahead in Diagnostics & Informatics

Get the weekly brief in your inbox — the developments, what they mean by vantage, and what to do next.